BR112017018209A2 - produtos terapêuticos de polipeptídeo e usos dos mesmos - Google Patents

produtos terapêuticos de polipeptídeo e usos dos mesmos

Info

Publication number
BR112017018209A2
BR112017018209A2 BR112017018209-2A BR112017018209A BR112017018209A2 BR 112017018209 A2 BR112017018209 A2 BR 112017018209A2 BR 112017018209 A BR112017018209 A BR 112017018209A BR 112017018209 A2 BR112017018209 A2 BR 112017018209A2
Authority
BR
Brazil
Prior art keywords
enzymes
therapeutic polypeptide
polypeptide products
respects
compositions
Prior art date
Application number
BR112017018209-2A
Other languages
English (en)
Inventor
O. Williams Robert
Idell Steven
Shetty Sreerama
Original Assignee
Board Of Regents, The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Regents, The University Of Texas System filed Critical Board Of Regents, The University Of Texas System
Publication of BR112017018209A2 publication Critical patent/BR112017018209A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

trata-se de métodos e composição para a entrega de enzimas na via aérea de um indivíduo. em alguns aspectos, a composição nebulizada de enzimas, tais como ativadores de plasminogênio, é fornecida. em aspectos adicionais, as composições de perfluorocarbono que compreendem enzimas, tais como ativadores de plasminogênio, são fornecidas. as composições podem ser, em alguns aspectos, usadas para o tratamento de infecções pulmonares ou lesão pulmonar aguda, tal como lesão pulmonar aguda induzida por fumaça inalacional (isali).
BR112017018209-2A 2015-02-27 2016-02-26 produtos terapêuticos de polipeptídeo e usos dos mesmos BR112017018209A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562126039P 2015-02-27 2015-02-27
US62/126,039 2015-02-27
PCT/US2016/019827 WO2016138413A1 (en) 2015-02-27 2016-02-26 Polypeptide therapeutics and uses thereof

Publications (1)

Publication Number Publication Date
BR112017018209A2 true BR112017018209A2 (pt) 2018-04-17

Family

ID=55587353

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017018209-2A BR112017018209A2 (pt) 2015-02-27 2016-02-26 produtos terapêuticos de polipeptídeo e usos dos mesmos

Country Status (10)

Country Link
US (3) US20180050084A1 (pt)
EP (2) EP4056194A1 (pt)
JP (2) JP6866296B2 (pt)
KR (1) KR102698051B1 (pt)
CN (1) CN107405379A (pt)
AU (1) AU2016225111B2 (pt)
BR (1) BR112017018209A2 (pt)
CA (1) CA2977519A1 (pt)
HK (1) HK1247111A1 (pt)
WO (1) WO2016138413A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018208547A1 (en) * 2017-05-10 2018-11-15 University Of Massachusetts Bivalent dengue/hepatitis b vaccines
EP3849581A4 (en) * 2018-09-10 2022-07-06 Board of Regents, The University of Texas System DRY POWDER FORMULATION OF CAVEOLIN-1 PEPTIDES AND METHODS OF USING THE SAME
JP7496826B2 (ja) * 2018-09-10 2024-06-07 ラング セラピューティクス，エルエルシー Ｃａｖ－１タンパク質の修飾ペプチドフラグメント及び線維症の治療におけるその使用
WO2020106922A1 (en) * 2018-11-21 2020-05-28 Board Of Regents, The University Of Texas System Peptide therapeutics for acute and chronic airway and alveolar diseases
US20240082342A1 (en) * 2018-11-21 2024-03-14 Board Of Regents, The University Of Texas System Peptide therapeutics for increasing lung cell viability
WO2020185826A1 (en) * 2019-03-11 2020-09-17 Lung Therapeutics, Inc. Compositions and methods for protecting type 2 alveolar epithelial cells (aec2)
WO2021160092A1 (zh) * 2020-02-11 2021-08-19 泰伦基国际有限公司 一种治疗病毒性肺炎的方法和药物

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5938117A (en) 1991-04-24 1999-08-17 Aerogen, Inc. Methods and apparatus for dispensing liquids as an atomized spray
US6540154B1 (en) 1991-04-24 2003-04-01 Aerogen, Inc. Systems and methods for controlling fluid feed to an aerosol generator
US6629646B1 (en) 1991-04-24 2003-10-07 Aerogen, Inc. Droplet ejector with oscillating tapered aperture
US5277175A (en) 1991-07-12 1994-01-11 Riggs John H Continuous flow nebulizer apparatus and method, having means maintaining a constant-level reservoir
GB9120005D0 (en) 1991-09-19 1991-11-06 Wellcome Found Method of administering phospholipid dispersions
US5355872B1 (en) 1992-03-04 1998-10-20 John H Riggs Low flow rate nebulizer apparatus and method of nebulization
US5284133A (en) 1992-07-23 1994-02-08 Armstrong Pharmaceuticals, Inc. Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means
US5329028A (en) 1992-08-05 1994-07-12 Genentech, Inc. Carbohydrate-directed cross-linking reagents
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
EP0848625A1 (en) 1995-09-06 1998-06-24 Steven L. Ryder Variable oxygen concentration high-flow nebulizer
US5823179A (en) 1996-02-13 1998-10-20 1263152 Ontario Inc. Nebulizer apparatus and method
ES2140998B1 (es) 1996-05-13 2000-10-16 Univ Sevilla Procedimiento de atomizacion de liquidos.
US20030113271A1 (en) * 1997-01-29 2003-06-19 University Technology Corporation Formulations for pulmonary delivery
IT1291122B1 (it) 1997-03-28 1998-12-29 Sar Spa Micropompa per la nebulizzazione di fluidi con valvola dosatrice perfezionata
US6096707A (en) * 1997-07-11 2000-08-01 Biotie Therapies Ltd. Integrin binding peptide and use thereof
US6044841A (en) 1997-08-29 2000-04-04 1263152 Ontario Inc. Breath actuated nebulizer with valve assembly having a relief piston
US6041776A (en) 1998-05-14 2000-03-28 Briggs, Iii; Stephen W. Medical nebulization device
US6354516B1 (en) 1999-11-02 2002-03-12 Aradigm Corporation Pore structures for reduced pressure aerosolization
SE9900369D0 (sv) 1999-02-04 1999-02-04 Siemens Elema Ab Ultrasonic nebuliser
US6328030B1 (en) 1999-03-12 2001-12-11 Daniel E. Kidwell Nebulizer for ventilation system
AU2001280917A1 (en) 2000-08-02 2002-02-13 Research Development Foundation Jet nebulizer assembly for home administration of drugs in aerosols
US20020077283A1 (en) * 2000-09-08 2002-06-20 Sessa William C. Caveolin peptides and their use as therapeutics
US6732944B2 (en) 2001-05-02 2004-05-11 Aerogen, Inc. Base isolated nebulizing device and methods
US7360536B2 (en) 2002-01-07 2008-04-22 Aerogen, Inc. Devices and methods for nebulizing fluids for inhalation
AU2003203043A1 (en) 2002-01-15 2003-07-30 Aerogen, Inc. Methods and systems for operating an aerosol generator
WO2003086278A2 (en) 2002-04-05 2003-10-23 Board Of Regents, The University Of Texas System Intrapleural single-chain urokinase alone or complexed to its soluble receptor protects against pleural adhesions
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US20070207158A1 (en) 2003-06-17 2007-09-06 Harrison Roger G Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof
UA94711C2 (uk) 2005-05-25 2011-06-10 Аэроджен, Инк. Вібраційна система (варіанти) та спосіб її виготовлення (варіанти), спосіб вібрування пластини (варіанти), система виробництва аерозолю та спосіб лікування пацієнта
TWI299993B (en) * 2005-12-15 2008-08-21 Dev Center Biotechnology Aqueous inhalation pharmaceutical composition
KR20100098697A (ko) * 2007-12-13 2010-09-08 글락소 그룹 리미티드 폐 전달을 위한 조성물
WO2009111625A2 (en) * 2008-03-05 2009-09-11 Board Of Regents, The University Of Texas System Peptide inhibition of lung epithelial apoptosis and pulmonary fibrosis
US20110171193A1 (en) * 2008-06-12 2011-07-14 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating pulmonary hypertension
TWI508735B (zh) * 2008-10-21 2015-11-21 巴克斯特國際公司 凍乾的重組ｖｗｆ調配物
JP5951508B2 (ja) * 2010-02-11 2016-07-13 アブリンクス エン．ヴェー． エアロゾルの調製のための方法及び組成物
KR102588702B1 (ko) * 2013-03-15 2023-10-16 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 누트린-3a 및 펩티드에 의한 폐 섬유증의 저해
CN104274827B (zh) * 2013-07-01 2020-07-14 上海贺普药业股份有限公司 贺普拉肽的制剂
EP3849581A4 (en) * 2018-09-10 2022-07-06 Board of Regents, The University of Texas System DRY POWDER FORMULATION OF CAVEOLIN-1 PEPTIDES AND METHODS OF USING THE SAME
WO2020106922A1 (en) * 2018-11-21 2020-05-28 Board Of Regents, The University Of Texas System Peptide therapeutics for acute and chronic airway and alveolar diseases
US20220276652A1 (en) * 2021-03-01 2022-09-01 The Boeing Company Autonomous maneuver generation to mate connectors

Also Published As

Publication number Publication date
US20180050084A1 (en) 2018-02-22
EP3261657A1 (en) 2018-01-03
US20210330741A1 (en) 2021-10-28
JP2021080285A (ja) 2021-05-27
KR20170122748A (ko) 2017-11-06
AU2016225111A1 (en) 2017-08-31
CN107405379A (zh) 2017-11-28
WO2016138413A1 (en) 2016-09-01
CA2977519A1 (en) 2016-09-01
EP4056194A1 (en) 2022-09-14
US20200164028A1 (en) 2020-05-28
KR102698051B1 (ko) 2024-08-26
HK1247111A1 (zh) 2018-09-21
JP6866296B2 (ja) 2021-04-28
JP2018507867A (ja) 2018-03-22
AU2016225111B2 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
BR112017018209A2 (pt) produtos terapêuticos de polipeptídeo e usos dos mesmos
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112014019431A8 (pt) Método compartimentalizado de distribuição de ácido nucleico e composições e usos desses
BR112017007892A2 (pt) composição, e, preparação injetável.
PH12019502725A1 (en) Use of lactic acid bacteria to treat or prevent at least one of postnatal depression and postnatal anxiety
BR112019009113A2 (pt) formulações de vírus adenoassociado
BR112015016293A2 (pt) derivados de benzilamina
BR112017023380A2 (pt) sistema, composição cosmética, métodos para tratamento de substratos queratinosos e para proteção e/ou alisamento da fibra do cabelo, kit multicompartimento, e, processo para alisamento do cabelo.
BR112016015818A2 (pt) Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1
MX2022006948A (es) Composiciones y metodos para programar celulas terapeuticas utilizando nanoportadores de acidos nucleicos dirigidos.
BR112017014060A2 (pt) composições de bacillus licheniformis rti184 e métodos de uso para beneficiar o crescimento de plantas
BR112015005227A2 (pt) inibidores de glicosilceramida sintase
CL2018000033A1 (es) Composición para destapar una nariz tapada que tiene actividad antiviral.
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
MX2014004814A (es) Compuestos y metodos para mejorar las respuestas inmunes innatas.
MX2022014634A (es) Metodos para la administracion linfatica de agentes activos.
BR112017020039A2 (pt) composição farmacêutica, kit, método, processo para preparar uma composição e solução farmacêutica
JO3122B1 (ar) مشتقات إسترا-5،3،1(10)، 16- تترايين-3- كربوكساميد، عمليات لتحضيرها، مستحضرات دوائية تشتمل عليها واستخدامها لتحضير أدوية
MX2022002946A (es) Inhibidores de cdk y su uso como productos farmaceuticos.
MX2019008999A (es) Composicion inyectable para prevenir la perdida del pelo o estimular el crecimiento del pelo.
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
WO2014140103A3 (en) Thrombin sensitive coagulation factor x molecules
WO2012051339A3 (en) Methods and compositions for treating respiratory conditions using platelet enriched plasma
BR112019017393A2 (pt) formulações de evolocumab de baixa viscosidade, alta concentração e métodos para produzir as mesmas
BR112017005828A2 (pt) métodos para tratar ou prevenir uma infecção respiratória, copd e uma exacerbação de copd e para selecionar um inibidor de sinalização notch 3 e/ou notch4, usp de um inibidor de sinalização de notch 3 e/ou notch 4, inibidor de sinalização de notch 3 e/ou notch 4, e, composição farmacêutica.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.